( (CODE <begin_1471-230X-2-21>))

( (NP (NN Background)))

( (S (NP-SBJ (NP (JJ Primary) (NNP Sj¶gren) (POS 's))
	     (NN syndrome)
	     (CODE -LRB-)
	     (PRN (NP (NNP 1°SS))))
     (CODE -RRB-)
     (VP (VBZ is)
	 (NP-PRD (NP (DT a) (JJ systemic) (JJ autoimmune) (NN disorder))
		 (VP (VBN characterized)
		     (NP (-NONE- *))
		     (PP (IN by)
			 (NP-LGS (NP (JJ dry)
				     (NNS eyes)
				     (CODE -LRB-)
				     (PRN (NP (FW keratoconjunctivitis) (FW sicca))))
				 (CODE -RRB-)
				 (, ,)
				 (NP (JJ dry)
				     (NN mouth)
				     (CODE -LRB-)
				     (PRN (NP (FW xerostomia))))
				 (CODE -RRB-)
				 (CONJP (RB as) (RB well) (IN as))
				 (NP (NP (NN involvement))
				     (PP (IN of)
					 (NP (JJ other) (JJ exocrine) (NNS glands)))))))))
     (. .)))

( (S (SBAR-TMP (IN While)
	       (S (NP-SBJ-1 (NNP 1°SS))
		  (VP (VBZ is)
		      (ADVP-MNR (RB typically))
		      (VP (VBN considered)
			  (S (NP-SBJ (-NONE- *-1))
			     (NP-PRD (DT an) (JJ autoimmune) (NN exocrinopathy)))))))
     (, ,)
     (NP-SBJ (DT the) (JJ immune) (NN destruction))
     (VP (MD can)
	 (ADVP-TMP (RB often))
	 (VP (VB extend)
	     (S (NP-SBJ (-NONE- *PRO*))
		(VP (TO to)
		    (VP (VB affect)
			(NP (JJ non-exocrine) (NNS organs)))))))
     (. .)))

( (SBAR-ADV (IN Around)
	    (S (NP-SBJ (NP (CD 25) (NN %))
		       (PP (IN of)
			   (NP (NP (NNS patients))
			       (PP (IN with)
				   (NP (NNP 1°SS))))))
	       (VP (MD can)
		   (VP (VB present)
		       (PP-CLR (IN with)
			       (NP (NP (NN involvement))
				   (PP (IN of)
				       (NP (NP (JJ other) (NNS organs))
					   (PP (JJ such)
					       (IN as)
					       (NP (NP (DT the) (NN thyroid))
						   (NP (, ,)
						       (JJ central)
						       (JJ nervous)
						       (NML (NN system) (, ,) (NNS lungs))
						       (, ,)
						       (NN kidney)
						       (CC and)
						       (NN liver)))))))))))
	    (. .)))

( (S (NP-SBJ-1 (NP (DT The) (NN association))
	       (PP (IN of)
		   (NP (NP (NN liver) (NN disease))
		       (CC and)
		       (NP (NNP 1°SS)))))
     (VP (VBD was)
	 (VP (VBN suggested)
	     (NP (-NONE- *-1))
	     (ADVP-TMP (NP (QP (JJR more) (IN than) (CD 40))
			   (NNS years))
		       (RB ago))))
     (CODE {COM:footnote_indexical_omitted})
     (. .)))

( (S (SBAR-ADV (IN While)
	       (S (NP-SBJ-1 (NP (NN liver) (NN involvement))
			    (PP (IN in)
				(NP (NNP 1°SS))))
		  (VP (VBZ has)
		      (VP (VBN been)
			  (VP (VBN considered)
			      (S (NP-SBJ (-NONE- *-1))
				 (" ")
				 (ADJP-PRD (JJ rare))))))))
     (" ")
     (CODE COM:footnote_indexicals_omitted})
     (NP-SBJ (QP (RB only) (DT a) (JJ few))
	     (JJ clinical)
	     (NNS studies))
     (ADVP-MNR (RB specifically))
     (VP (VP (VBP address)
	     (NP (DT this) (NN complication)))
	 (CC and)
	 (VP (VBP evaluate)
	     (NP (NP (DT the) (NN association))
		 (PP (IN of)
		     (NP (NML (NN liver) (NN function))
			 (NNS tests)
			 (NNS abnormalities))))
	     (PP (IN with)
		 (NP (NP (DT the) (NN severity))
		     (PP (IN of)
			 (NP (NNP 1°SS)))))))
     (CODE {COM:footnote_indexicals_omitted})
     (. .)))

( (S (NP-SBJ (NP (NN Liver) (NNS diseases))
	     (VP (VBN associated)
		 (NP (-NONE- *))
		 (PP-CLR (IN with)
			 (NP (NNP 1°SS)))))
     (VP (VBP include)
	 (NP (NP (JJ primary)
		 (JJ biliary)
		 (NN cirrhosis)
		 (CODE -LRB-)
		 (PRN (NP (NN PBC))))
	     (CODE -RRB-)
	     (HYPH -)
	     (NP (JJ autoimmune) (NN cholangitis))
	     (CODE {COM:footnote_indexicals_omitted})
	     (, ,)
	     (NP (JJ autoimmune) (NN hepatitis))
	     (CODE {COM:footnote_indexicals_omitted})
	     (, ,)
	     (NP (JJ viral)
		 (NN hepatitis)
		 (CODE -LRB-)
		 (QP (NN B) (CC and) (NN C)))
	     (CODE -RRB-)
	     (CODE {COM:footnote_indexicals_omitted})
	     (, ,)
	     (NP (JJ sclerosing) (NN cholangitis))
	     (CODE {COM:footnote_indexicals_omitted})
	     (, ,)
	     (CC and)
	     (NP (JJ nodular) (JJ regenerative) (NN hyperplasia))))
     (CODE {COM:footnote_indexicals_omitted})
     (. .)))

( (S (PP (IN In)
	 (NP (NN addition)))
     (NP-SBJ (, ,) (JJ chronic) (JJ lymphocytic) (NN sialadenitis))
     (VP (VBZ has)
	 (VP (VBN been)
	     (VP (VBN found)
		 (PP-LOC (IN in)
			 (NP (NP (NNS patients))
			     (PP (IN with)
				 (NP (NP (JJ different) (NNS types))
				     (PP (IN of)
					 (NP (NN liver)
					     (NN cirrhosis)
					     (QP (CODE <bracket>) (CD 16) (CD 17) (CD 18) (CD 19) (CD 20) (CD 21) (CD 22) (CD 23) (CD 24)))))))))))
     (CODE <$$bracket>)
     (. .)))

( (S (NP-SBJ (PRP We))
     (VP (VBP report)
	 (NP (NP (DT the) (NNS results))
	     (PP (IN of)
		 (NP (NP (NP (DT a) (NN review))
			 (PP (IN of)
			     (NP (NNS cases))))
		     (VP (VBN undertaken)
			 (NP (-NONE- *))
			 (S-PRP (NP-SBJ (-NONE- *PRO*))
				(VP (TO to)
				    (VP (VB determine)
					(NP (NP (NP (NP (DT the) (NN prevalence))
						    (PP (IN of)
							(NP (NP (JJ abnormal)
								(NML (NN liver) (NN function))
								(NNS tests)
								(CODE -LRB-)
								(PRN (NP (NNS LFTs))))
							    (CODE -RRB-)
							    (CC and)
							    (NP (NN liver) (NN disease)))))
						(PP (IN in)
						    (NP (NP (NNS patients))
							(PP (IN with)
							    (NP (NNP 1°SS)))
							(VP (VBN referred)
							    (NP (-NONE- *))
							    (PP (IN to)
								(NP (DT a)
								    (NML (JJ tertiary) (NN care))
								    (NN center)))))))
					    (CC and)
					    (NP (NP (DT the) (NN association))
						(PP (IN of)
						    (NP (JJ abnormal) (NNS LFTs)))
						(PP (IN with)
						    (NP (NP (JJ other)
							    (NML (NML (JJ systemic) (NNS features))
								 (CC and)
								 (NML (NN autoimmunity) (NNS markers))))
							(PP (IN of)
							    (NP (NNP 1°SS)))))))))))))))
     (. .)))

( (NP (NNS Methods)))

( (NP (JJ Statistical) (NN analysis)))

( (S (NP-SBJ (DT The) (JJ statistical) (NN analysis))
     (VP (VBD included)
	 (NP (NP (JJ descriptive) (NNS measures))
	     (CODE -LRB-)
	     (NP (NP (NNS means))
		 (, ,)
		 (NP (JJ standard) (NNS deviations))
		 (CC and)
		 (NP (NNS ranges)))))
     (CODE -RRB-)
     (. .)))

( (S (NP-SBJ-1 (NP (NN Comparison))
	       (PP (IN of)
		   (NP (NP (NNS results))
		       (PP (IN of)
			   (NP (NP (NNS patients))
			       (PP (IN with)
				   (CC and)
				   (IN without)
				   (NP (NN liver) (NN disease))))))))
     (VP (VBD was)
	 (VP (VBN done)
	     (NP (-NONE- *-1))
	     (S-ADV (NP-SBJ (-NONE- *PRO*))
		    (VP (VBG using)
			(NP (NP (NP (NNS t-tests))
				(PP (IN of)
				    (NP (JJ continuous) (NNS variables))))
			    (CC and)
			    (NP (NP (NP (NNP Fisher) (POS 's))
				    (JJ exact)
				    (NN test))
				(CC or)
				(NP (NN x2))))
			(PP-PRP (IN for)
				(NP (JJ categoric) (NNS measures)))))))
     (. .)))

( (NP (NNS Results)))

( (S (PP-TPC-1 (IN Of)
	       (NP (NP (DT the) (CD 115) (NNS charts))
		   (VP (VBN reviewed)
		       (NP (-NONE- *)))))
     (, ,)
     (NP-SBJ-2 (NP (CD 73) (NNS cases))
	       (PP (-NONE- *T*-1))
	       (CODE -LRB-)
	       (PRN (FRAG (NP (NP (CD 55) (NNS women))
			      (CC and)
			      (NP (CD 18) (NNS men)))
			  (, ,)
			  (NP (JJ median) (NN age))
			  (NP (CD 53)))))
     (CODE -RRB-)
     (VP (VP (VBD fulfilled)
	     (NP (NP (NN EECC))
		 (PP (IN for)
		     (NP (NNP 1°SS)))))
	 (CC and)
	 (VP (VBD were)
	     (ADVP-TMP (RB initially))
	     (VP (VBN included)
		 (NP (-NONE- *-2))
		 (PP-PRP (IN for)
			 (NP (NN analysis))))))
     (. .)))

( (S (PP-TPC (IN Of)
	     (NP (DT the) (CD 73) (NNS patients)))
     (, ,)
     (NP-SBJ (NP (DT a) (CD 54) (NN %))
	     (PP (IN of)
		 (NP (PRP them)))
	     (CODE -LRB-)
	     (PRN (NP (CD 40) (NNS patients))))
     (VP (CODE -RRB-)
	 (VBP have)
	 (VP (VBN had)
	     (S (NP-SBJ-1 (DT a) (JJ salivary) (NN gland) (NN biopsy))
		(VP (VBN performed)
		    (NP (-NONE- *-1)))))) 
     (. .)))

( (S (PP (IN In)
	 (NP (PDT all) (DT these) (NNS patients)))
     (, ,)
     (NP-SBJ (DT the) (NN biopsy))
     (VP (VBD confirmed)
	 (NP (NP (DT the) (NN diagnosis))
	     (PP (IN of)
		 (NP (NP (NNP Sj¶gren) (POS 's))
		     (NN syndrome)))))
     (. .)))

( (S (NP-SBJ (NP (DT All) (NNS patients))
	     (VP (VBN studied)
		 (NP (-NONE- *))))
     (VP (VBD had)
	 (NP (NP (NP (JJ objective) (NN evidence))
		 (PP (IN of)
		     (NP (NNP 1°SS))))
	     (, ,)
	     (PP (VBG including)
		 (NP (NP (FW keratoconjunctivitis) (FW sicca))
		     (, ,)
		     (NP (JJ positive)
			 (NML (JJ labial) (JJ salivary) (NN gland))
			 (NN biopsy))
		     (, ,)
		     (NP (NNS autoantibodies))
		     (CONJP (CC and) (SYM $$) (CC or))
		     (NP (NML (JJ salivary) (NN gland))
			 (NN hypofunction))))))
     (. .)))

( (S (NP-SBJ (PRP We))
     (VP (VBD excluded)
	 (NP (NP (NP (DT those) (NNS patients))
		 (PP (IN without)
		     (NP (NP (DT these) (JJ objective) (NNS criteria))
			 (PP (IN of)
			     (NP (NNP 1°SS))))))
	     (CONJP (CC and) (RB also))
	     (NP (NP (DT those))
		 (SBAR (WHNP-1 (WP who))
		       (S (NP-SBJ (-NONE- *T*-1))
			  (VP (VBD did)
			      (RB not)
			      (VP (VB fulfill)
				  (NP (NN EECC) (NNS criteria)))))))))
     (. .)))

( (S (S (NP-SBJ (NP (DT The) (JJ mean) (NN age))
		(PP (IN at)
		    (NP (NP (NN time))
			(PP (IN of)
			    (NP (NP (NN onset))
				(PP (IN of)
				    (NP (NN disease))))))))
	(VP (VBD was)
	    (ADJP-PRD (NML (QP (CD 45) (SYM ±) (CD 20.5))
			   (NNS years))
		      (JJ old))))
     (CC and)
     (S (NP-SBJ (NN disease) (NN duration))
	(VP (VBD was)
	    (NP-PRD (NP (CD 4.9) (NNS years))
		    (SYM ±)
		    (NP (CD 4.5) (NNS years))
		    (CODE -LRB-)
		    (PRN (NP (JJ mean))
			 (SYM ±)
			 (NP (NN range))))))
     (CODE -RRB-)
     (. .)))

( (S (S (NP-SBJ-1 (NML (NN Liver) (NN function))
		  (NNS tests))
	(VP (VBD had)
	    (VP (VBN been)
		(VP (VBN determined)
		    (NP (-NONE- *-1))
		    (PP-LOC (IN in)
			    (NP (CD 59)
				(NNS patients)
				(CODE -LRB-)
				(PRN (NP (CD 80.8) (NN %)))))))))
     (CODE -RRB-)
     (CC and)
     (S (NP-SBJ-2 (JJ abnormal)
		  (NML (NN liver) (NN function))
		  (NNS tests))
	(VP (VBD were)
	    (VP (VBN found)
		(NP (-NONE- *-2))
		(PP (IN in)
		    (NP (QP (CD 29) (IN of) (DT the) (CD 59))
			(NNS patients)
			(CODE -LRB-)
			(PRN (NP (CD 49.1) (NN %))))))))
     (CODE -RRB-)
     (. .)))

( (S (NP-SBJ-1 (JJR Further) (NN analysis))
     (VP (VBD was)
	 (ADVP-TMP (RB then))
	 (VP (VBN undertaken)
	     (NP (-NONE- *-1))
	     (PP (IN in)
		 (NP (NP (DT those) (NNS patients))
		     (SBAR (WHPP-2 (IN in)
				   (WHNP (WP whom)))
			   (S (NP-SBJ-3 (NNS LFTs))
			      (VP (VBD had)
				  (VP (VBN been)
				      (VP (VBN measured)
					  (NP (-NONE- *-3))
					  (PP (-NONE- *T*-2)))))))))))
     (. .)))

( (S (NP-SBJ (NP (DT The) (JJ clinical) (CC and) (NN laboratory) (NNS characteristics))
	     (PP (IN of)
		 (NP (DT these) (NNS patients))))
     (VP (VBP are)
	 (VP (VBN shown)
	     (PP-LOC (IN in)
		     (NP (NP (NNS Tables))
			 (NP (QP (CD 2) (CC and) (CD 3)))))))
     (. .)))

( (S (PP (IN For)
	 (NP (NP (DT these) (NNP SS) (NNS patients))
	     (VP (VBN studied)
		 (NP (-NONE- *)))))
     (, ,)
     (NP-SBJ (JJ abnormal) (NNS LFTs))
     (VP (VBD were)
	 (ADJP-PRD (ADJP (RBR more) (JJ common))
		   (PP (IN than)
		       (NP (NP (DT any) (JJ other) (JJ potential) (JJ non-exocrine) (NNS features))
			   (PP (IN of)
			       (NP (NNP SS)))))))
     (. .)))

( (S (NP-SBJ-1 (NP (NP (JJ Clinical) (NN evidence))
		   (PP (IN of)
		       (NP (NN liver) (NN disease))))
	       (, ,)
	       (VP (VBN defined)
		   (NP (-NONE- *))
		   (PP (IN in)
		       (NP (NNS methods) (NN section)))))
     (, ,)
     (VP (VBD was)
	 (VP (VBN found)
	     (NP (-NONE- *-1))
	     (PP-LOC (IN in)
		     (NP (NP (CD 12)
			     (NNS patients)
			     (CODE -LRB-)
			     (QP (CD 20.3) (NN %)))
			 (CODE -RRB-)
			 (, ,)
			 (SBAR (WHNP-2 (WHNP (DT all))
				       (WHPP (IN of)
					     (WHNP (WP whom))))
			       (S (NP-SBJ (-NONE- *T*-2))
				  (VP (VBD had)
				      (NP (JJ abnormal)
					  (NML (NN liver) (NN function))
					  (NNS tests)))))))))
     (. .)))

( (S (NP-SBJ (CD Two) (NNS deaths))
     (VP (VBD occurred)
	 (PP (IN in)
	     (NP (NP (DT the) (NN population))
		 (VP (VBN studied)
		     (NP (-NONE- *)))))
	 (, ,)
	 (S-ADV (NP-SBJ-1 (DT both))
		(VP (VBN attributed)
		    (NP (-NONE- *-1))
		    (PP (IN to)
			(NP (NN liver) (NN failure))))))
     (. .)))

( (S (NP-SBJ (DT An) (JJ additional) (NN patient))
     (VP (VBD required)
	 (NP (DT a) (NN liver) (NN transplant)))
     (. .)))

( (S (PP (IN In)
	 (NP (DT all) (NNS cases)))
     (, ,)
     (NP-SBJ (NP (DT the) (NN diagnosis))
	     (PP (IN of)
		 (NP (NNP 1°SS))))
     (VP (VBD antedated)
	 (NP (NP (NP (DT the) (NN onset))
		 (PP (IN of)
		     (NP (NN liver) (NN disease))))
	     (CC or)
	     (NP (PRP$ its) (NN diagnosis))))
     (. .)))

( (S (NP-SBJ-1 (NP (NNS Markers))
	       (PP (IN of)
		   (NP (JJ viral) (NN hepatitis)))
	       (, ,)
	       (VP (VBN sought)
		   (NP (-NONE- *))
		   (PP-LOC (IN in)
			   (NP (CD 39) (NNS patients)))))
     (, ,)
     (VP (VBD were)
	 (VP (VBN found)
	     (NP (-NONE- *-1))
	     (PP-LOC (ADVP (RB only))
		     (IN in)
		     (NP (CD 4)))))
     (. .)))

( (S (S (NP-SBJ (CD Two) (NNS patients))
	(VP (VBD carried)
	    (NP (NP (DT the) (NN surface) (NN antigen))
		(PP (IN of)
		    (NP (NML (NN hepatitis) (NN B))
			(NN virus))))))
     (CC and)
     (S (NP-SBJ (CD one))
	(VP (VBD had)
	    (NP (NNS antibodies))
	    (PP (IN to)
		(NP (NML (NN hepatitis) (NN C))
		    (NN virus)))))
     (. .)))

( (S (PP-TMP (IN In)
	     (NP (NP (DT a) (NN liver) (NN biopsy))
		 (PP (IN of)
		     (NP (NP (DT a) (NN patient))
			 (SBAR (WHNP-1 (WP who))
			       (S (NP-SBJ (-NONE- *T*-1))
				  (VP (VBD lacked)
				      (NP (NP (JJ serological) (NNS markers))
					  (PP (IN for)
					      (NP (NN hepatitis) (NNS viruses)))))))))))
     (, ,)
     (NP-SBJ-2 (NML (NN hepatitis) (NN B))
	       (NN virus))
     (VP (VBD was)
	 (VP (VBN detected)
	     (NP (-NONE- *-2))
	     (PP-LGS (IN by)
		     (NP (ADJP (FW in) (FW situ))
			 (NN hybridization)))))
     (. .)))

( (S (NP-SBJ-1 (NP (NN Risk) (NNS factors))
	       (PP (IN for)
		   (NP (NN liver) (NN disease))))
     (VP (VBD were)
	 (VP (VP (VBN identified)
		 (NP (-NONE- *-1))
		 (PP-LOC (IN in)
			 (NP (NP (CD 40) (NN %))
			     (PP (IN of)
				 (NP (NP (DT the) (NNS patients))
				     (PP (IN with)
					 (NP (JJ abnormal)
					     (NML (NN liver) (NN function))
					     (NNS tests))))))))
	     (CC and)
	     (VP (VBP are)
		 (VP (VBN described)
		     (NP (-NONE- *-1))
		     (PP-LOC (IN in)
			     (NP (NN Table) (CD 4)))))))
     (. .)))

( (S (NP-SBJ (NP (DT No) (NN association))
	     (PP (IN with)
		 (NP (NN tobacco) (NN use))))
     (VP (VBD was)
	 (VP (VBN found)))
     (. .)))

( (S (NP-SBJ (QP (RB Only) (CD 5))
	     (NNS patients))
     (VP (VBD had)
	 (VP (VBN documented)
	     (NP (NP (NN evidence))
		 (PP (IN of)
		     (NP (NN tobacco) (NN consumption))))))
     (. .)))

( (S (NP-SBJ (PRP We))
     (VP (VBD found)
	 (NP (NP (DT no) (JJ significant) (NNS differences))
	     (PP (IN in)
		 (NP (NP (NN risk) (NNS factors))
		     (PP (IN for)
			 (NP (JJ abnormal)
			     (NML (NN liver) (NN function))
			     (NNS tests))))))
	 (PP (IN among)
	     (NP (NP (NNS patients))
		 (PP (IN with)
		     (CC or)
		     (IN without)
		     (NP (JJ hepatic) (NN involvement))))))
     (. .)))

( (S (ADVP (RB Therefore))
     (, ,)
     (PP (IN in)
	 (NP (NP (QP (CD 60) (NN %) (IN of))
		 (DT the)
		 (NNS patients))
	     (PP (IN with)
		 (NP (NP (ADJP (ADJP (GW sub) (JJ clinical))
			       (CC or)
			       (ADJP (JJ clinical)))
			 (NN evidence))
		     (PP (IN of)
			 (NP (NN liver) (NN disease)))))))
     (, ,)
     (NP-SBJ-1 (NP (DT no) (JJ clear) (NN explanation))
	       (PP (IN for)
		   (NP (DT the) (JJ abnormal) (NNS LFTs))))
     (VP (VBD was)
	 (VP (VBN found)
	     (NP (-NONE- *-1))
	     (, ,)
	     (PP (IN except)
		 (PP (IN for)
		     (NP (NP (DT the) (NN association))
			 (PP (IN with)
			     (NP (NNP 1°SS))))))))
     (. .)))

( (S (NP-SBJ (NP (DT The) (NN pattern))
	     (PP (IN of)
		 (NP (JJ biochemical) (NN liver) (NNS abnormalities))))
     (VP (VP (VBD was)
	     (ADVP (RB mainly))
	     (ADJP-PRD=1 (ADJP (JJ hepatocellular))
			 (CODE -LRB-)
			 (VP (VBN defined)
			     (NP (-NONE- *))
			     (PP-CLR (IN as)
				     (NP (NP (JJ predominant) (NN increase))
					 (PP (IN of)
					     (NP (NNP AST) (CC and) (SYM $$) (CC or) (NN ALT)))
					 (PP (IN in)
					     (NP (NP (NN comparison))
						 (PP (IN with)
						     (NP (NNP AP) (CC and) (SYM $$) (CC or) (NN bilirubins)))))))))
	     (CODE -RRB-)
	     (PP=2 (IN in)
		   (NP (CD 11) (NNS cases))))
	 (, ;)
	 (VP (ADJP-PRD=1 (ADJP (JJ cholestatic))
			 (CODE -LRB-)
			 (VP (VBN defined)
			     (NP (-NONE- *))
			     (PP-CLR (IN as)
				     (NP (NP (JJ predominant) (NN increase))
					 (PP (IN in)
					     (NP (NN AP) (CC and) (SYM $$) (CC or) (NN bilirubins)))
					 (VP (VBN compared)
					     (NP (-NONE- *))
					     (PP-CLR (IN with)
						     (NP (NN AST) (CC and) (SYM $$) (CC or) (NN ALT))))))))
	     (CODE -RRB-)
	     (PP=2 (IN in)
		   (NP (CD 3))))
	 (CC and)
	 (VP (ADJP-PRD=1 (VBN mixed)
			 (CODE -LRB-)
			 (PRN (NP (NN evidence))
			      (PP (IN of)
				  (NP (ADJP (CC both) (JJ cholestatic) (CC and) (JJ hepatocellular))
				      (NN damage)))))
	     (CODE -RRB-)
	     (PP=2 (IN in)
		   (NP (CD 8) (NNS cases)))))
     (. .)))

( (S (S (NP-SBJ (NNS Abnormalities))
	(VP (VP (VBD were)
		(ADJP-PRD=1 (JJ persistent)
			    (CODE -LRB-)
			    (PRN (FRAG (ADJP (JJ present))
				       (PP-TMP (IN on)
					       (NP (DT every) (NN occasion)))
				       (SBAR-TMP (WHADVP-2 (WRB when))
						 (S (NP-SBJ-3 (-NONE- *PRO*))
						    (VP (VBN measured)
							(NP (-NONE- *-3))
							(ADVP-TMP (ADVP (RBR more))
								  (PP (IN than)
								      (ADVP (RB once))))
							(ADVP-TMP (-NONE- *T*-2))))))))
		(CODE -RRB-)
		(PP=4 (IN in)
		      (NP (NP (CD 19) (NNS patients))
			  (CODE -LRB-)
			  (QP (QP (CD 65.5) (NN %))
			      (PP (IN of)
				  (NP (NP (DT those))
				      (PP (IN with)
					  (NP (JJ abnormal) (NNS LFTs)))))))))
	    (CODE -RRB-)
	    (, ,)
	    (VP (ADJP-PRD=1 (JJ intermittent)
			    (CODE -LRB-)
			    (PRN (S (NP-SBJ-5 (NP (NN presence))
					      (PP (IN of)
						  (NP (NN LFT) (NNS abnormalities))))
				    (VP (VBD was)
					(RB not)
					(VP (VBN found)
					    (NP (-NONE- *-5))
					    (PP (IN in)
						(NP (DT all) (NNS determinations))))))))
		(CODE -RRB-)
		(PP=4 (IN in)
		      (NP (NP (CD 9))
			  (CODE -LRB-)
			  (QP (CD 31) (NN %)))))))
     (CODE -RRB-)
     (CC and)
     (S (PP (IN in)
	    (NP (NP (CD one) (NN case))
		(CODE -LRB-)
		(QP (CD 3.5) (NN %))))
	(CODE -RRB-)
	(NP-SBJ (EX there))
	(VP (VBD was)
	    (NP-PRD (NP (QP (RB only) (CD one))
			(NN determination))
		    (PP (IN of)
			(NP (NML (NN liver) (NN function))
			    (NNS tests))))))
     (. .)))

( (S (NP-SBJ-1 (NP (DT The) (NN pattern))
	       (PP (IN of)
		   (NP (NML (NN liver) (NN enzyme))
		       (NNS abnormalities))))
     (VP (VBZ is)
	 (VP (VBN shown)
	     (NP (-NONE- *-1))
	     (PP-LOC (IN in)
		     (NP (NN Figure) (CD 1)))))
     (. .)))

( (S (NP-SBJ (NP (NN None))
	     (PP (IN of)
		 (NP (NP (DT the) (NNS patients))
		     (PP (IN with)
			 (NP (JJ abnormal)
			     (NML (NN liver) (NN function))
			     (NNS tests))))))
     (VP (VBD had)
	 (NP (NP (NP (JJ clinical) (NN evidence))
		 (PP (IN of)
		     (NP (NN muscle) (NN involvement))))
	     (SBAR (WHNP-1 (WDT that))
		   (S (NP-SBJ (-NONE- *T*-1))
		      (VP (MD could)
			  (VP (VB explain)
			      (NP (NP (DT the) (JJ high) (NNS levels))
				  (PP (IN of)
				      (NP (NNS amino-transferases))))))))))
     (. .)))

( (S (NP-SBJ-1 (NP (NN Activity))
	       (PP (IN of)
		   (NP (NNP CPK) (CC or) (NN aldolase))))
     (VP (VBD was)
	 (RB not)
	 (ADJP-PRD (VBN elevated))
	 (SBAR-TMP (WHADVP-2 (WRB when))
		   (S (NP-SBJ-3 (-NONE- *PRO*-1))
		      (VP (VBN measured)
			  (NP (-NONE- *-3))
			  (ADVP-TMP (-NONE- *T*-2)))))
	 (PP (IN in)
	     (NP (NP (CD 15))
		 (PP (IN of)
		     (NP (NP (DT the) (CD 29) (NNS patients))
			 (PP (IN with)
			     (NP (JJ abnormal)
				 (NML (NN liver) (NN function))
				 (NNS tests))))))))
     (. .)))

( (S (NP-SBJ-1 (NP (JJ Anti-mitochondrial)
		   (NNS antibodies)
		   (CODE -LRB-)
		   (PRN (NP (NNS AMA))))
	       (CODE -RRB-)
	       (CC and)
	       (NP (ADJP (JJ anti-smooth) (NN muscle))
		   (NNS antibodies)
		   (CODE -LRB-)
		   (PRN (NP (NNS ASMA)))))
     (CODE -RRB-)
     (VP (VBD were)
	 (VP (VBN sought)
	     (NP (-NONE- *-1))
	     (PP-LOC (IN in)
		     (NP (CD 5) (NNS patients)))
	     (, ,)
	     (PP (IN with)
		 (S-NOM (NP-SBJ (JJ positive) (NNS ASMA))
			(PP-PRD (IN in)
				(NP (CD 2)))))))
     (. .)))

( (S (NP-SBJ-1 (NP (DT The) (NN association))
	       (PP (IN of)
		   (NP (JJ abnormal)
		       (NML (NN liver) (NN function))
		       (NNS tests)))
	       (PP (IN with)
		   (NP (NP (JJ other) (NN non-exocrine) (NNS features))
		       (PP (IN of)
			   (NP (NNP 1°SS))))))
     (VP (VBZ is)
	 (VP (VBN shown)
	     (NP (-NONE- *-1))
	     (PP-LOC (IN in)
		     (NP (NN Figure) (CD 2)))))
     (. .)))

( (S (NP-SBJ-1 (NP (NNS Patients))
	       (PP (IN with)
		   (NP (JJ abnormal)
		       (NML (NN liver) (NN function))
		       (NNS tests))))
     (VP (VBD were)
	 (ADJP-PRD (ADJP (RBR more) (JJ likely))
		   (S (NP-SBJ (-NONE- *-1))
		      (VP (TO to)
			  (VP (VB have)
			      (NP (NML (NN lung) (, ,) (NN kidney) (CC or) (JJ hematological))
				  (NNS manifestations))))))
	 (, ,)
	 (SBAR-TMP (WHADVP-2 (WRB when))
		   (S (NP-SBJ-3 (-NONE- *PRO*-1))
		      (VP (VBN compared)
			  (NP (-NONE- *-3))
			  (PP-CLR (IN to)
				  (NP (NP (NP (NNP Sj¶gren) (POS 's))
					  (NNS patients))
				      (PP (IN without)
					  (NP (NN liver) (NN disease)))))
			  (ADVP-TMP (-NONE- *T*-2))))))
     (. .)))

( (S (NP-SBJ-1 (NP (NN Presence))
	       (PP (IN of)
		   (NP (NP (JJ other) (JJ non-exocrine) (NNS features))
		       (PP (IN of)
			   (NP (NNP 1°SS))))))
     (VP (VBD was)
	 (RB not)
	 (VP (VBN influenced)
	     (NP (-NONE- *-1))
	     (PP (IN by)
		 (NP-LGS (NP (NN prevalence))
			 (PP (IN of)
			     (NP (NN liver) (NNS diseases)))))))
     (. .)))

( (S (PP (IN Regarding)
	 (NP (NML (NN laboratory) (NN test))
	     (NNS results)))
     (, ,)
     (NP-SBJ (NP (NNS patients))
	     (PP (IN with)
		 (NP (NN liver) (NN disease))))
     (VP (VBD were)
	 (ADJP-PRD (ADJP (RBR more) (JJ likely))
		   (S (NP-SBJ (-NONE- *PRO*))
		      (VP (TO to)
			  (VP (VB have)
			      (NP (DT an) (VBN elevated) (NN sedimentation) (NN rate))
			      (PP-TMP (IN at)
				      (NP (DT some) (NN point)))
			      (PP-TMP (IN during)
				      (NP (NP (DT the) (NN course))
					  (PP (IN of)
					      (NP (PRP$ their) (NN disease))))))))))
     (. .)))

( (S (NP-SBJ-1 (NP (DT A) (JJ positive) (JJ anti-ENA))
	       (CODE -LRB-)
	       (NP (NP (JJ anti-Ro))
		   (, ,)
		   (NP (JJ anti-Ro) (SYM $$) (JJ La))
		   (, ,)
		   (CONJP (CC and) (SYM $$) (CC or))
		   (NP (JJ anti-RNP))))
     (CODE -RRB-)
     (VP (VBD was)
	 (ADVP (RB also))
	 (VP (VBN associated)
	     (NP (-NONE- *-1))
	     (PP-CLR (IN with)
		     (NP (NP (DT an) (VBN increased) (NN prevalence))
			 (PP (IN of)
			     (NP (JJ abnormal)
				 (NML (NN liver) (NN function))
				 (NNS tests)))))))
     (CODE -LRB-)
     (REF (NP (NN Figure) (CD 3)))
     (CODE -RRB-)
     (. .)))

( (S (NP-SBJ (DT The) (NN sample))
     (VP (VBD was)
	 (ADJP-PRD (ADJP (RB too) (JJ small))
		   (S (NP-SBJ (-NONE- *PRO*))
		      (VP (TO to)
			  (VP (VB determine)
			      (SBAR (IN whether)
				    (S (NP-SBJ-1 (DT a) (JJ specific) (NN ENA))
				       (VP (VBD was)
					   (VP (VBN associated)
					       (NP (-NONE- *-1))
					       (PP-CLR (IN with)
						       (NP (NN liver) (NN disease))))))))))))
     (. .)))

( (S (NP-SBJ (NP (JJ Other) (NNS markers))
	     (PP (IN of)
		 (NP (JJ systemic) (NN inflammation) (CC or) (NN autoimmunity))))
     (VP (VBD did)
	 (RB not)
	 (VP (VB correlate)
	     (PP-CLR (IN with)
		     (NP (NP (DT the) (NN presence) (CC or) (NN absence))
			 (PP (IN of)
			     (NP (NN LFT) (NNS abnormalities)))))))
     (. .)))

( (S (NP-SBJ (NP (NN Liver) (NNS biopsies))
	     (, ,)
	     (VP (VBN done)
		 (NP (-NONE- *))
		 (PP-LOC (IN in)
			 (NP (CD 8) (NNS patients)))))
     (, ,)
     (VP (VBD disclosed)
	 (NP (NP (JJ post-viral)
		 (JJ chronic)
		 (JJ active)
		 (NN hepatitis)
		 (CODE -LRB-)
		 (PRN (NP (CD 3))))
	     (CODE -RRB-)
	     (, ,)
	     (NP (JJ cryptogenic)
		 (NN cirrhosis)
		 (CODE -LRB-)
		 (PRN (NP (CD 2))))
	     (CODE -RRB-)
	     (, ,)
	     (CC and)
	     (NP (NP (CD one) (NN case))
		 (PP (RB each)
		     (IN of)
		     (NP (NP (JJ post-viral) (NN cirrhosis))
			 (, ,)
			 (NP (JJ alcoholic) (NN hepatitis))
			 (, ,)
			 (CC and)
			 (NP (JJ autoimmune) (NN hepatitis)))))))
     (. .)))

( (NP (NN Discussion)))

( (S (PP-LOC (IN In)
	     (NP (NP (NP (DT this) (NN group))
		     (PP (IN of)
			 (NP (NP (NNP Sj¶gren) (POS 's))
			     (NNS patients))))
		 (VP (VBN seen)
		     (NP (-NONE- *))
		     (PP-LOC (IN at)
			     (NP (DT a)
				 (NML (JJ tertiary) (NN care))
				 (NN center))))))
     (, ,)
     (NP-SBJ-1 (JJ abnormal)
	       (NML (NN liver) (NN function))
	       (NNS tests))
     (VP (VBD were)
	 (VP (VBN found)
	     (S (NP-SBJ (-NONE- *-1))
		(VP (TO to)
		    (VP (VB be)
			(NP-PRD (NP (DT a) (JJ common) (JJ non-exocrine) (NN feature))
				(PP (IN of)
				    (NP (NNP 1°SS)))))))))
     (. .)))

( (S (NP-SBJ-1 (NP (DT The) (NN prevalence))
	       (PP (IN of)
		   (NP (DT this) (NN association))))
     (VP (VBD was)
	 (VP (VBN found)
	     (S (NP-SBJ (-NONE- *-1))
		(VP (TO to)
		    (VP (VB be)
			(ADJP-PRD (ADJP (JJR higher))
				  (PP (-NONE- *ICH*-2)))
			(PP (IN in)
			    (NP (PRP$ our) (NN study)))
			(PP-2 (IN than)
			      (PP (IN in)
				  (NP (JJ other) (JJ previous) (NN series)))))))))
     (CODE {COM:footnote_markers_omitted})
     (. .)))

( (S (NP-SBJ (DT The) (JJ true) (NN prevalence))
     (VP (MD could)
	 (VP (VB be)
	     (ADJP-PRD (RB even) (JJR higher))
	     (SBAR-PRP (IN since)
		       (S (NP-SBJ-1 (NML (NN liver) (NN enzyme))
				    (NNS profiles))
			  (VP (VBD were)
			      (RB not)
			      (VP (VBN done)
				  (NP (-NONE- *-1))
				  (PP (IN in)
				      (NP (DT all) (NNS patients)))))))))
     (. .)))

( (S (S (NP-SBJ (NP (DT The) (NN prevalence))
		(VP (VBN suggested)
		    (NP (-NONE- *))
		    (PP (IN in)
			(NP (JJ previous) (NNS reports)))))
	(VP (VBZ ranges)
	    (PP-CLR (PP (IN from)
			(NP (CD 6)))
		    (PP (IN to)
			(NP (CD 58) (NN %))))))
     (, ,)
     (CC but)
     (S (NP-SBJ (NP (DT the) (NN definition))
		(PP (IN of)
		    (NP (JJ hepatic) (NN disease))))
	(VP (VBZ varies)
	    (PP (PP (IN from)
		    (NP (NP (DT the) (JJ unspecific))
			(CODE -LRB-)
			(NP (ADVP (FW e.g.))
			    (NN hepatomegaly))))
		(CODE -RRB-)
		(PP (IN to)
		    (NP (NP (ADJP (RB well) (VBN proven))
			    (NNS cases))
			(PP (IN of)
			    (NP (NN liver) (NN disease))))))))
     (CODE {COM:footnote_indexicals_omitted})
     (. .)))

( (S (NP-SBJ (NP (NNP Denko))
	     (PP (IN in)
		 (NP (NN 1960))))
     (VP (VBD reported)
	 (SBAR (IN that)
	       (S (NP-SBJ (NP (CD 12) (NN %))
			  (PP (IN of)
			      (NP (NP (NNS patients))
				  (PP (IN with)
				      (NP (NNP SS))))))
		  (VP (VBD had)
		      (NP (NN hepatosplenomegaly) (CODE <bracket>) (CD 29))))))
     (CODE <$$bracket>)
     (. .)))

( (S (NP-SBJ (NP (JJ Other) (NNS studies))
	     (VP (VBN done)
		 (NP (-NONE- *))
		 (PP-TMP (IN in)
			 (NP (DT the) (NNS 1960's)))))
     (ADVP (RB also))
     (VP (VBD confirmed)
	 (NP (NN hepatomegaly))
	 (PP (IN in)
	     (NP (NP (QP (CD 18) (SYM -) (CD 20))
		     (NN %))
		 (PP (IN of)
		     (NP (NP (NNS patients))
			 (PP (IN with)
			     (NP (NNP SS))))))))
     (CODE {COM:footnote_indexicals_omitted})
     (. .)))

( (S (PP-TMP (IN In)
	     (NP (NN 1970)))
     (, ,)
     (NP-SBJ (NNP Whaley))
     (VP (VP (VBD reported)
	     (NP (NP (NN liver) (NN disease))
		 (PP (IN in)
		     (NP (NP (QP (CD 6) (NN %) (IN of))
			     (NNS patients))
			 (PP (IN with)
			     (NP (NNP SS)))))))
	 (CC and)
	 (VP (VBD mentioned)
	     (NP (NP (DT an) (NN association))
		 (PP (IN with)
		     (NP (JJ anti-mitochondrial) (NNS antibodies))))))
     (CODE {COM:footnote_indexicals_omitted})
     (. .)))

( (S (S (PP-TMP (IN In)
		(NP (NN 1986)))
	(, ,)
	(NP-SBJ (NNP Tsianos) (CC and) (NNS co-workers))
	(VP (VBD described)
	    (NP (NP (CD 22) (NNP SS) (NNS patients))
		(PP (IN with)
		    (NP (JJ gastrointestinal) (NNS complications)))
		(, ,)
		(VP (VBN called)
		    (NP (-NONE- *))
		    (PP (IN from)
			(NP (DT a) (JJ large) (NN cohort)))))))
     (, ;)
     (S (NP-SBJ (QP (RB only) (CD two))
		(NNS patients))
	(VP (VBD had)
	    (NP (NN liver) (NN disease))
	    (, ,)
	    (S-ADV (NP-SBJ (DT each))
		   (PP-PRD (IN with)
			   (NP (JJ chronic) (JJ active) (NN hepatitis))))))
     (CODE {COM:footnote_indexical_omitted})
     (. .)))

( (S (NP-SBJ (JJ Other) (NNS studies))
     (VP (VBP have)
	 (VP (VBN reported)
	     (NP (NP (NP (JJ variable) (NN prevalence))
		     (CODE {COM:footnote_indexicals_omitted})
		     (CC and)
		     (NP (JJ different) (JJ histopathological) (NNS findings)))
		 (VP (-NONE- *ICH*-1)))
	     (PP (IN in)
		 (NP (NN liver) (NNS biopsies)))
	     (VP-1 (VBG ranging)
		   (PP (PP (IN from)
			   (NP (NP (JJ cholestatic) (NN liver) (NN damage))
			       (CODE -LRB-)
			       (NP (NML (NN stage) (CD I))
				   (JJ primary)
				   (JJ biliary)
				   (NN cirrhosis))))
		       (CODE -RRB-)
		       (PP (IN to)
			   (NP (NP (JJ chronic) (JJ active) (NN hepatitis))
			       (ADJP (ADJP (JJ due))
				     (PP (IN to)
					 (NP (NML (NN hepatitis) (NN C))
					     (NN virus))))))))))
     (. .)))

( (S (PP (IN In)
	 (NP (PRP$ our) (NN study)))
     (, ,)
     (NP-SBJ-1 (NN liver) (NN disease))
     (VP (VBD was)
	 (VP (VBN associated)
	     (NP (-NONE- *-1))
	     (PP-CLR (IN with)
		     (NP (NP (JJ other) (JJ non-exocrine) (NNS manifestations))
			 (PP (IN of)
			     (NP (NNP 1°SS)))
			 (, ,)
			 (RRC (ADVP (RB specifically))
			      (NP (NP (DT those))
				  (VP (VBG affecting)
				      (NP (NML (NN lung) (, ,) (NN kidney) (CC and) (NN blood))
					  (NNS cells)))))))))
     (. .)))

( (S (NP-SBJ-1 (NP (DT Those) (NNS patients))
	       (PP (IN with)
		   (NP (NP (NP (JJ serological) (NN evidence))
			   (PP (IN of)
			       (NP (JJ systemic) (NN inflammation))))
		       (, ,)
		       (SBAR (IN as)
			     (S (NP-SBJ-2 (-NONE- *PRO*))
				(VP (VBN shown)
				    (NP (-NONE- *-2))
				    (PP (IN by)
					(NP-LGS (DT an) (VBN elevated) (NN sedimentation) (NN rate)))))))))
     (, ,)
     (VP (VBD were)
	 (ADJP-PRD (ADJP (RBR more) (JJ likely))
		   (S (NP-SBJ (-NONE- *-1))
		      (VP (TO to)
			  (VP (VB have)
			      (NP (NML (NN liver) (NN test))
				  (NNS abnormalities)))))))
     (. .)))

( (S (ADVP (RB Also))
     (, ,)
     (NP-SBJ (NP (DT the) (NN presence))
	     (PP (IN of)
		 (NP (DT a) (JJ positive) (JJ anti-ENA))))
     (VP (VBD correlated)
	 (ADVP (RB positively))
	 (PP (IN with)
	     (NP (JJ hepatic) (NN disease))))
     (. .)))

( (S (NP-SBJ-1 (NP (DT An) (NN association))
	       (PP (IN of)
		   (NP (NN ENA) (NN response)))
	       (PP (IN with)
		   (NP (NN liver) (NN disease))))
     (VP (VBZ has)
	 (VP (VBN been)
	     (VP (VBN described)
		 (NP (-NONE- *-1))
		 (PP-LOC (IN in)
			 (NP (NP (NP (NNS children))
				 (PP (IN with)
				     (NP (JJ autoimmune) (NN hepatitis))))
			     (, ,)
			     (SBAR (WHADVP-2 (WRB where))
				   (S (NP-SBJ (JJ anti-ENA-positive) (NNS patients))
				      (VP (VBD demonstrated)
					  (NP (NP (ADJP (RBR more) (JJ severe))
						  (NML (NN liver) (NN test))
						  (NNS abnormalities))
					      (PP (IN than)
						  (NP (NP (DT those))
						      (SBAR (WHNP-3 (WP who))
							    (S (NP-SBJ (-NONE- *T*-3))
							       (VP (VBD were)
								   (ADJP-PRD (JJ anti-ENA-negative))))))))
					  (ADVP-LOC (-NONE- *T*-2))))))))))
     (CODE {COM:footnote_markers_omitted})
     (. .)))

( (S (PP (IN In)
	 (NP (DT another) (NN study)))
     (, ,)
     (NP-SBJ-1 (NP (QP (DT a) (CD 15) (NN %) (IN of))
		   (NNS patients))
	       (PP (IN with)
		   (NP (JJ various) (JJ chronic) (NN liver) (NNS diseases))))
     (VP (VBD were)
	 (VP (VBN found)
	     (S (NP-SBJ (-NONE- *-1))
		(VP (TO to)
		    (VP (VB be)
			(NP-PRD (JJ anti-RNP) (JJ positive)))))))
     (CODE {COM:footnote_markers_omitted})
     (. .)))

( (S (PP (IN With)
	 (S-NOM (NP-SBJ (NP (NN etiopathogenesis))
			(PP (IN of)
			    (NP (NNP 1°SS))))
		(ADVP-TMP (RB still))
		(NP-PRD (DT an) (JJ open) (NN question))))
     (CODE {COM:footnote_indexicals_omitted})
     (, ,)
     (NP-SBJ (NP (DT a) (JJ possible) (NN role))
	     (PP (IN of)
		 (NP (NML (NN hepatitis) (NN C))
		     (NN virus)
		     (CODE -LRB-)
		     (PRN (NP (NN HCV))))))
     (CODE -RRB-)
     (VP (VBZ has)
	 (VP (VBN drawn)
	     (NP (NN attention))))
     (. .)))

( (S (NP-SBJ (JJ Recent) (NNS studies))
     (VP (VBP have)
	 (VP (VBN mentioned)
	     (NP (NN HCV) (NN incidence))
	     (PP (IN in)
		 (NP (NP (NNS patients))
		     (PP (IN with)
			 (NP (NP (NNP 1SS))
			     (VP (VBG ranging)
				 (PP-CLR (IN from)
					 (NP (QP (CD 14) (IN -) (CD 19))
					     (NN %))))))))))
     (CODE {COM:footnote_markers_omitted})
     (. .)))

( (S (NP-SBJ (NP (JJ Phenotypic) (NN characterization))
	     (PP (IN of)
		 (NP (DT the) (JJ minor) (JJ salivary) (NNS glands)))
	     (PP (IN with)
		 (NP (NN immunohistochemistry)))
	     (PP (IN in)
		 (NP (NP (NNS patients))
		     (PP (IN with)
			 (NP (NP (NML (NML (NN hepatitis) (NN C))
				      (NN virus))
				 (NN infection))
			     (CONJP (CC and) (SYM $$) (CC or))
			     (NP (NNP 1°SS)))))))
     (VP (VBZ has)
	 (VP (VBN given)
	     (NP (JJ conflicting) (NNS results))))
     (CODE {COM:footnote_indexicals_omitted})))

( (S (NP-SBJ (DT Some) (NNS reports))
     (VP (VBP mention)
	 (SBAR (IN that)
	       (S (NP-SBJ (DT the)
			  (NML (JJ salivary) (NN gland))
			  (NNS findings))
		  (VP (VBP are)
		      (ADJP-PRD (RB strikingly) (JJ similar))
		      (PP (IN in)
			  (NP (NP (NNS patients))
			      (PP (IN with)
				  (NP (NP (NN liver) (NN disease))
				      (VP (VBN associated)
					  (NP (-NONE- *))
					  (PP-CLR (IN with)
						  (NP (NN HCV) (NN infection))))))))
		      (PP (IN than)
			  (PP (IN in)
			      (NP (NP (DT those))
				  (PP (IN with)
				      (NP (NNP 1°SS)))))))))
	 (CODE {COM:footnote_indexicals_omitted})
	 (, ,)
	 (SBAR-ADV (IN while)
		   (S (NP-SBJ (NNS others))
		      (VP (VBP mention)
			  (NP (NP (JJ distinctive) (NNS differences))
			      (PP (IN between)
				  (NP (DT both) (NNS groups)))
			      (PP (VBG regarding)
				  (NP (NP (NN focus) (NN score))
				      (, ,)
				      (NP (NP (NN expression))
					  (PP (IN of)
					      (NP (NN surface) (NNS markers)))
					  (PP (PP (IN in)
						  (NP (NP (NNS lymphocytes))
						      (VP (VBG infiltrating)
							  (NP (DT the) (JJ salivary) (NNS glands)))))
					      (CC and)
					      (PP (IN in)
						  (NP (JJ epithelial) (NNS cells)))))
				      (, ,)
				      (CONJP (RB as) (RB well) (IN as))
				      (NP (NP (NNS differences))
					  (PP (IN in)
					      (NP (NP (DT the) (NN degree))
						  (PP (IN of)
						      (NP (NN inflammation)))))))))))))
     (CODE {COM:footnote_indexicals_omitted})
     (. .)))

( (S (NP-SBJ (NP (JJ Transgenic) (NN mice) (NNS models))
	     (SBAR (WHNP-1 (WDT that))
		   (S (NP-SBJ (-NONE- *T*-1))
		      (VP (VBP carry)
			  (NP (DT the)
			      (NML (NN HCV) (NN envelope))
			      (NNS genes))))))
     (VP (VBP develop)
	 (NP (NP (DT an) (NN exocrinopathy))
	     (VP (VBG affecting)
		 (NP (ADJP (JJ salivary) (CC and) (JJ lachrymal))
		     (NNS glands)))))
     (CODE {COM:footnote_markers_omitted})
     (. .)))

( (S (NP-SBJ-1 (NP (NN Expression))
	       (PP (IN of)
		   (NP (NN autoimmunity) (NNS markers))))
     (ADVP (RB also))
     (VP (VBZ tends)
	 (S (NP-SBJ (-NONE- *-1))
	    (VP (TO to)
		(VP (VB differ))))
	 (PP (IN between)
	     (NP (NP (NN HCV) (HYPH -) (NN infection))
		 (CC and)
		 (NP (NNP 1°SS)))))
     (. .)))

( (S (NP-SBJ (JJ Positive) (NNS ENAs))
     (VP (VBP are)
	 (ADVP-TMP (RB rarely))
	 (VP (VBN seen)
	     (PP-LOC (IN in)
		     (NP (NN HCV) (HYPH -) (NNS patients)))))
     (. .)))

( (S (ADVP (RB Also))
     (, ,)
     (PP (IN in)
	 (NP (RBS most) (NNS cases)))
     (NP-SBJ (NN sicca) (NNS symptoms))
     (VP (VBP are)
	 (RB not)
	 (ADJP-PRD (JJ present))
	 (PP (IN in)
	     (NP (NP (NNS individuals))
		 (PP (IN with)
		     (NP (NN HCV)))))
	 (SBAR-ADV (IN as)
		   (S (NP-SBJ-1 (-NONE- *PRO*))
		      (VP (VBN compared)
			  (NP (-NONE- *-1))
			  (PP-CLR (IN with)
				  (NP (DT the) (NNP 1°SS) (NN population)))))))
     (. .)))

( (S (SBAR-ADV (IN Although)
	       (S (NP-SBJ (NP (DT the) (NN prevalence))
			  (PP (IN of)
			      (NP (NML (JJ viral) (NN hepatitis))
				  (NNS markers)))
			  (PP (IN in)
			      (NP (NP (PRP$ our) (NN group))
				  (PP (IN of)
				      (NP (NP (NNS patients))
					  (PP (IN with)
					      (NP (NN liver) (NN disease))))))))
		  (VP (VP (VBD was)
			  (ADJP-PRD (RB very) (JJ low)))
		      (CC and)
		      (VP (VBD did)
			  (RB not)
			  (VP (VB account)
			      (PP-CLR (IN for)
				      (NP (NP (RBS most))
					  (PP (IN of)
					      (NP (NP (DT the) (NNS cases))
						  (PP (IN with)
						      (NP (NML (JJ abnormal) (NN liver) (NN function))
							  (NNS tests))))))))))))
     (, ,)
     (NP-SBJ-1 (DT these) (NNS markers))
     (VP (VBD were)
	 (RB not)
	 (VP (VBN sought)
	     (NP (-NONE- *-1))
	     (PP (IN in)
		 (NP (NP (DT a) (JJ small) (NN percentage))
		     (PP (IN of)
			 (NP (DT these) (NNS patients)))))))
     (. .)))

( (S (NP-SBJ (NP (PRP It))
	     (S (-NONE- *EXP*-1)))
     (VP (VBZ is)
	 (ADJP-PRD (JJ important))
	 (S-1 (NP-SBJ (-NONE- *PRO*))
	      (VP (TO to)
		  (VP (VB note)
		      (SBAR (IN that)
			    (S (NP-SBJ-2 (NN HCV))
			       (VP (VBZ appears)
				   (S (NP-SBJ (-NONE- *-2))
				      (VP (TO to)
					  (VP (VB account)
					      (PP-CLR (IN for)
						      (NP (NP (NP (DT a) (NN subgroup))
							      (PP (IN of)
								  (NP (NP (NNS patients))
								      (PP (IN with)
									  (NP (JJ exocrine) (NNS complaints))))))
							  (SBAR (WHPP-3 (IN in)
									(WHNP (WP which)))
								(S (NP-SBJ (PDT half) (DT the) (NNS cases))
								   (VP (MD might)
								       (VP (VB meet)
									   (NP (NP (DT the) (NN definition))
									       (PP (IN for)
										   (NP (NN SS))))
									   (PP (-NONE- *T*-3))
									   (PP (VBG according)
									       (PP (IN to)
										   (NP (UCP (JJ European) (CC and) (NNP Manthorpe))
										       (NNS criteria))))))))))))))))))))
     (. .)))

( (S (ADVP (RB However))
     (, ,)
     (NP-SBJ-1 (DT this) (NN subgroup))
     (VP (VBZ is)
	 (VP (VBN characterized)
	     (NP (-NONE- *-1))
	     (PP (IN by)
		 (NP-LGS (NP (NP (DT the) (NN absence))
			     (PP (IN of)
				 (NP (NP (JJ clinical) (NNS manifestations))
				     (VP (VBN observed)
					 (NP (-NONE- *))
					 (PP (IN in)
					     (NP (NNP 1°SS)))))))
			 (, ,)
			 (CC and)
			 (NP (NP (DT the) (NN absence))
			     (PP (IN of)
				 (NP (JJ anti-Ro) (CC and) (JJ anti-La))))))))
     (CODE {COM:footnote_indexicals_omitted})
     (. .)))

( (S (NP-SBJ-1 (NP (DT An) (JJ aberrant) (NN interaction))
	       (PP (IN between)
		   (NP (NP (NNS lymphocytes))
		       (CC and)
		       (NP (JJ different) (JJ epithelial) (NNS tissues)))))
     (VP (VBZ has)
	 (VP (VBN been)
	     (VP (VBN proposed)
		 (NP (-NONE- *-1))
		 (PP (IN as)
		     (NP (NP (DT a) (NN mechanism))
			 (PP (IN for)
			     (NP (NP (DT the) (NN damage))
				 (VP (VBN seen)
				     (NP (-NONE- *))
				     (PP (IN in)
					 (NP (JJ different) (NNPS organs)))
				     (PP (IN in)
					 (NP (NNP 1°SS)))))))))))
     (CODE {COM:footnote_indexicals_omitted})
     (. .)))

( (S (SBAR-ADV (IN Since)
	       (S (NP-SBJ-1 (NP (PRP it))
			    (SBAR (-NONE- *EXP*-2)))
		  (VP (VBZ has)
		      (VP (VBN been)
			  (VP (VBN suggested)
			      (NP (-NONE- *-1))
			      (SBAR-2 (IN that)
				      (S (NP-SBJ (NP (DT the) (NN target) (NN tissue))
						 (VP (VBN involved)
						     (NP (-NONE- *))
						     (PP-CLR (IN in)
							     (NP (NP (DT the) (JJ autoimmune) (JJ histopathologic) (NNS lesions))
								 (PP (IN of)
								     (NP (NNP 1°SS)))))))
					 (VP (MD might)
					     (VP (VB be)
						 (NP-PRD (DT the) (NN epithelium)))))))))))
     (CODE {COM:footnote_markers_omitted})
     (, ,)
     (NP-SBJ (NP (PRP it))
	     (SBAR (-NONE- *EXP*-3)))
     (VP (VBZ is)
	 (ADJP-PRD (JJ interesting))
	 (SBAR-3 (IN that)
		 (S (NP-SBJ (NP (DT the) (NNS findings))
			    (PP (IN in)
				(NP (PRP$ our) (NN study))))
		    (VP (VBP point)
			(PP-CLR (IN to)
				(NP (NP (NP (DT the) (NN association))
					(PP (IN of)
					    (NP (NN liver) (NN disease))))
				    (PP (IN with)
					(NP (NP (ADJP (JJ pulmonary) (CC and) (JJ renal))
						(NNS abnormalities))
					    (, ,)
					    (SBAR (WHNP-4 (PDT all) (WP which))
						  (S (NP-SBJ-5 (-NONE- *T*-4))
						     (VP (VBP are)
							 (VP (VBN characterized)
							     (NP (-NONE- *-5))
							     (PP (IN by)
								 (NP-LGS (JJ epithelial) (NN damage)))))))))))))))
     (CODE {COM:footnote_markers_omitted})
     (. .)))

( (S (S (NP-SBJ-1 (JJ Epithelial) (NNS cells))
	(VP (VBP have)
	    (VP (VBN been)
		(VP (VBN proposed)
		    (NP-2 (-NONE- *-1))
		    (S (NP-SBJ (-NONE- *PRO*-2))
		       (VP (TO to)
			   (VP (VB be)
			       (NP-PRD (NP (JJ active) (NNS participants))
				       (PP (IN rather)
					   (IN than)
					   (NP (JJ passive) (NNS targets)))
				       (PP (IN in)
					   (NP (DT the) (JJ chronic) (JJ immune) (NN response))))
			       (PP (IN in)
				   (NP (NNP 1°SS))))))))))
     (CC but)
     (S (NP-SBJ-2 (JJR further) (NNS studies))
	(VP (VBP are)
	    (VP (VBN needed)
		(NP (-NONE- *-2))
		(S-PRP (NP-SBJ (-NONE- *PRO*))
		       (VP (TO to)
			   (VP (VB establish)
			       (NP (NP (NP (DT the) (NN role))
				       (PP (IN of)
					   (NP (NN liver) (JJ epithelial) (NNS cells))))
				   (PP (IN in)
				       (NP (NP (DT the) (NN pathogenesis))
					   (PP (IN of)
					       (NP (JJ hepatic) (NN damage)))
					   (PP (IN in)
					       (NP (DT this) (NN disease)))))))))
		(, ,)
		(PP (VBG including)
		    (NP (NP (DT the) (NN analysis))
			(PP (IN of)
			    (NP (NML (NML (NN HLA) (NN expression))
				     (CC and)
				     (NML (NN cytokine) (NN secretion)))
				(NN pattern)))
			(PP (IN in)
			    (NP (DT these) (NNS cells))))))))
     (. .)))

( (S (NP-SBJ-1 (NP (DT The) (NN co-existence))
	       (PP (IN of)
		   (NP (NP (NN liver) (NN disease))
		       (CC and)
		       (NP (NP (DT the) (NN presence))
			   (PP (IN of)
			       (NP (VBG circulating) (NNS AMAs)))
			   (PP (IN in)
			       (NP (NP (NP (NNP Sj¶gren) (POS 's))
				       (NNS patients)
				       (POS '))
				   (CODE {TEXT:patients})
				   (NN sera)))))))
     (VP (VBZ has)
	 (VP (VBN been)
	     (VP (VBN pointed)
		 (NP (-NONE- *-1))
		 (PP-CLR (IN as)
			 (NP (NP (DT an) (NN indicator))
			     (SBAR (IN that)
				   (S (NP-SBJ (NN liver) (NN pathology))
				      (VP (MD might)
					  (VP (VB be)
					      (ADJP-PRD (ADJP (JJ autoimmune))
							(CC and)
							(ADJP (ADJP (JJ similar))
							      (PP (IN to)
								  (NP (NP (DT that))
								      (PP (IN of)
									  (NP (JJ primary) (JJ biliary) (NN cirrhosis))))))))))))))))
     (CODE {COM:footnote_indexicals_omitted})
     (. .)))

( (S (PP (IN In)
	 (NP (JJ previous) (NNS studies)))
     (, ,)
     (NP-SBJ-1 (NP (NP (DT a) (JJ pericholangial) (JJ lymphocytic) (NN infiltration))
		   (ADJP (ADJP (JJ similar))
			 (PP (IN to)
			     (NP (NP (DT that))
				 (VP (VBN found)
				     (NP (-NONE- *))
				     (PP-LOC (IN in)
					     (NP (NP (NN stage) (CD I))
						 (PP (IN of)
						     (NP (JJ primary) (JJ biliary) (NN cirrhosis)))))))))))
     (, ,)
     (VP (VBZ has)
	 (VP (VBN been)
	     (VP (VBN reported)
		 (NP (-NONE- *-1))
		 (PP-LOC (IN in)
			 (NP (NNP 1°SS)))
		 (PP (IN with)
		     (NP (NP (JJ abnormal)
			     (NML (NN liver) (NN function))
			     (NNS tests))
			 (CC or)
			 (NP (NP (NN positivity))
			     (PP (IN for)
				 (NP (NN AMA)))))))))
     (CODE {COM:footnote_indexicals_omitted})
     (. .)))

( (S (PP (IN In)
	 (NP (NP (PRP$ our) (NN review))
	     (PP (IN of)
		 (NP (NNS cases)))))
     (, ,)
     (NP-SBJ (PRP we))
     (VP (VBD found)
	 (NP (NP (NN predominance))
	     (PP (IN in)
		 (NP (NP (JJ hepatocellular) (NN liver) (NN damage))
		     (PP (RB rather)
			 (IN than)
			 (NP (JJ cholestatic) (NN disease))))))
	 (, ,)
	 (SBAR-ADV (WHNP-1 (WP which))
		   (S (NP-SBJ (-NONE- *T*-1))
		      (VP (MD would)
			  (VP (VB argue)
			      (PP-CLR (IN against)
				      (NP (NP (DT a) (NN PBC) (HYPH -) (NN type))
					  (PP (IN of)
					      (NP (NN liver) (NN damage))))))))))
     (. .)))

( (S (NP-SBJ (JJ Other) (NNS authors))
     (VP (VBD had)
	 (VP (VBN proposed)
	     (SBAR (IN that)
		   (S (NP-SBJ-1 (NP (NNP SS))
				(VP (VBN associated)
				    (NP (-NONE- *))
				    (PP-CLR (IN with)
					    (NP (NN PBC)))))
		      (VP (MD should)
			  (VP (VB be)
			      (VP (VBN considered)
				  (S (NP-SBJ (-NONE- *-1))
				     (NP-PRD (NP (NP (DT a))
						 (NN form)
						 (PP (IN of)
						     (NP (JJ secondary) (NNP SS))))
					     (SBAR (WHNP-2 (WDT that))
						   (S (NP-SBJ (-NONE- *T*-2))
						      (VP (VBZ resembles)
							  (ADVP-MNR (RBR more))
							  (NP (NP (DT the) (" ") (NN sicca) (NN complex))
							      (" ")
							      (PP (IN with)
								  (NP (NP (JJ exocrine) (NNS features))
								      (VP (VBN seen)
									  (NP (-NONE- *))
									  (PP (IN in)
									      (NP (NP (NNS patients))
										  (PP (IN with)
										      (NP (JJ rheumatoid) (NN arthritis)))))))))))))))))))))
     (CODE {COM:footnote_markers_omitted})
     (. .)))

( (S (NP-SBJ (NP (NNS Limitations))
	     (PP (IN of)
		 (NP (DT the) (NN study))))
     (VP (VBP come)
	 (ADVP-MNR (RB primarily))
	 (PP-CLR (IN from)
		 (S-NOM (NP-SBJ (-NONE- *PRO*))
			(VP (VBG being)
			    (NP-PRD (DT a) (JJ retrospective) (NN analysis))))))
     (. .)))

( (S (SBAR-PRP (IN Since)
	       (S (NP-SBJ-1 (DT the) (NNS patients))
		  (VP (VBD were)
		      (VP (VBN studied)
			  (NP (-NONE- *-1))
			  (PP-LOC (IN in)
				  (NP (DT a)
				      (NML (JJ tertiary) (NN care))
				      (NN referral)
				      (NN center)))))))
     (, ,)
     (NP-SBJ (NP (NP (DT the) (NN severity))
		 (PP (IN of)
		     (NP (DT the) (NN disease))))
	     (CC and)
	     (NP (NP (DT the) (NN prevalence))
		 (PP (IN of)
		     (NP (DT the) (NNS manifestations)))))
     (VP (MD might)
	 (VP (VB be)
	     (ADJP-PRD (ADJP (JJ different))
		       (PP (IN from)
			   (NP (DT the) (JJ general) (NNP 1�SS) (NN population))))))
     (. .)))

( (S (ADVP (RB Furthermore))
     (, ,)
     (PP (IN in)
	 (NP (JJ many) (NNS cases)))
     (, ,)
     (NP-SBJ-1 (NP (NNP Sj¶gren) (POS 's))
	       (NN syndrome)
	       (NN diagnosis))
     (VP (VBD had)
	 (VP (VBN been)
	     (VP (VBN sought)
		 (NP (-NONE- *-1))
		 (PP-PRP (IN because)
			 (IN of)
			 (NP (ADJP (RB otherwise) (JJ unexplained))
			     (JJ non-exocrine)
			     (NNS features))))))
     (. .)))

( (S (SBAR-ADV (IN While)
	       (S (NP-SBJ (PRP we))
		  (VP (MD could)
		      (RB not)
		      (VP (VB find)
			  (NP (NP (DT an) (NN association))
			      (PP (IN between)
				  (NP (NP (NP (NN use))
					  (PP (IN of)
					      (NP (NP (NNS NSAIDS))
						  (CC or)
						  (NP (JJ other) (NNS medications)))))
				      (CC and)
				      (NP (NP (NN prevalence))
					  (PP (IN of)
					      (NP (NML (NML (NN liver) (NN function))
						       (NNS tests))
						  (NNS abnormalities)))))))))))
     (, ,)
     (NP-SBJ (DT the) (NN study) (NN design))
     (VP (VBD did)
	 (RB not)
	 (VP (VB allow)
	     (S (NP-SBJ (PRP us))
		(VP (TO to)
		    (VP (VB exclude)
			(NP (NP (DT the) (NN possibility))
			    (PP (IN of)
				(NP (NP (NML (NML (PP (IN over)
						      (HYPH -)
						      (NP (DT the) (HYPH -) (NN counter)))
						  (CODE -LRB-)
						  (PRN (NML (JJ OTC))))
					     (CODE -RRB-)
					     (NN medication))
					(NN use))
				    (SBAR (WHNP-1 (WDT that))
					  (S (NP-SBJ (-NONE- *T*-1))
					     (VP (MD could)
						 (VP (VB have)
						     (VP (VBN affected)
							 (NP (NP (NN LFT) (POS 's))
							     (NN measurement)))))))))))))))
     (. .)))

( (S (NP-SBJ (NN Drug) (NN toxicity))
     (VP (VBZ is)
	 (ADVP (RB certainly))
	 (NP-PRD (NP (DT an) (JJ important) (NN factor))
		 (SBAR (WHNP-1 (-NONE- 0))
		       (S (NP-SBJ-2 (-NONE- *T*-1))
			  (VP (TO to)
			      (VP (VB be)
				  (VP (VBN considered)
				      (NP (-NONE- *-2)))))))))
     (. .)))

( (S (ADVP (RB However))
     (, ,)
     (S-ADV (NP-SBJ (-NONE- *PRO*))
	    (VP (VBN given)
		(SBAR (SBAR (IN that)
			    (S (NP-SBJ (RBS most) (NNS patients))
			       (VP (VBD had)
				   (NP (NP (ADJP (JJ persistent) (CC rather) (CC than) (JJ intermittent))
					   (NNS abnormalities))
				       (PP (IN of)
					   (NP (NNS LFTs)))))))
		      (CC and)
		      (SBAR (IN that)
			    (S (NP-SBJ-1 (NP (DT the) (NN use))
					 (PP (IN of)
					     (NP (JJ hepatotoxic) (NNS drugs))))
			       (VP (VBD was)
				   (RB not)
				   (VP (VBN elicited)
				       (NP (-NONE- *-1))
				       (PP (IN in)
					   (NP (NP (DT the) (NN majority))
					       (PP (IN of)
						   (NP (NP (NNS patients))
						       (PP (IN with)
							   (NP (NN liver) (NNS abnormalities))))))))))))))
     (, ,)
     (NP-SBJ-2 (NP (DT a) (JJ toxic) (NN effect))
	       (PP (IN of)
		   (NP (NNS medications))))
     (VP (MD could)
	 (RB not)
	 (VP (VB be)
	     (VP (VBN established)
		 (NP (-NONE- *-2)))))
     (. .)))

( (NP (NNS Conclusions)))

( (S (S-ADV (NP-SBJ-1 (-NONE- *PRO*))
	    (VP (VBN Based)
		(NP (-NONE- *-1))
		(PP-CLR (IN on)
			(NP (NP (DT the) (NNS results))
			    (PP (IN of)
				(NP (DT this) (NN study)))))))
     (, ,)
     (NP-SBJ (PRP we))
     (VP (VBP consider)
	 (SBAR (IN that)
	       (S (NP-SBJ-2 (NP (DT an) (NN evaluation))
			    (PP (IN for)
				(NP (NP (ADJP (JJ clinical) (CC and) (JJ serological))
					(NN evidence))
				    (PP (IN of)
					(NP (NN liver) (NN disease))))))
		  (VP (MD should)
		      (VP (VB be)
			  (VP (VBN done)
			      (NP (-NONE- *-2))
			      (PP (IN in)
				  (NP (NP (DT every) (NN patient))
				      (PP (IN with)
					  (NP (NNP 1°SS)))))
			      (, ,)
			      (SBAR-ADV (ADVP (RB particularly))
					(IN if)
					(S (NP-SBJ (EX there))
					   (VP (VBZ is)
					       (NP-PRD (NP (NP (NN evidence))
							   (PP (IN of)
							       (NP (JJ other) (JJ non-exocrine) (NNS complications))))
						       (CC or)
						       (NP (NP (JJ serological) (NN evidence))
							   (PP (IN of)
							       (NP (JJ systemic) (NN inflammation))))))))))))))
     (. .)))

( (S (SBAR-ADV (IN Although)
	       (S (NP-SBJ-1 (NP (DT no) (JJ other) (NN diagnosis))
			    (VP (VBG explaining)
				(NP (NN liver) (NN disease))))
		  (VP (MD may)
		      (VP (VB be)
			  (VP (VBN found)
			      (NP (-NONE- *-1)))))))
     (, ,)
     (NP-SBJ (NP (NP (DT the) (NNS disorders))
		 (SBAR (WHPP-2 (IN for)
			       (WHNP (WP which)))
		       (S (NP-SBJ (NN treatment))
			  (VP (MD might)
			      (VP (VB be)
				  (ADJP-PRD (JJ beneficial))
				  (PP (-NONE- *T*-2)))))))
	     (CODE -LRB-)
	     (FRAG (FW e.g.)
		   (FRAG (NP (NNS immunosuppressants))
			 (PP (IN for)
			     (NP (JJ autoimmune) (NN hepatitis))))
		   (, ,)
		   (FRAG (NP (NN interferon) (HYPH -) (NN alpha))
			 (PP (IN for)
			     (NP (JJ viral) (NN hepatitis))))
		   (, ,)
		   (FRAG (NP (JJ ursodeoxycolic) (NN acid))
			 (PP (IN for)
			     (NP (JJ primary) (JJ biliary) (NN cirrhosis))))))
     (CODE -RRB-)
     (VP (VBP warrant)
	 (NP (DT a) (JJ diligent) (NN search))
	 (PP (IN in)
	     (NP (NP (DT all) (NNS cases))
		 (PP (IN of)
		     (NP (NP (NNP 1°SS))
			 (PP (IN with)
			     (NP (JJ abnormal) (NN liver) (NN function))))))))
     (. .)))

( (NP (VBG Competing) (NNS interests)))

( (NP (NN None) (. .)))

( (UCP (NP (NP (NNS Authors) (POS '))
	   (NNS contributions))
       (S (NP-SBJ (DT Both) (NNS authors))
	  (VP (VBD contributed)
	      (ADVP (RB equally))
	      (PP (IN to)
		  (NP (DT the) (NN paper)))))
       (. .)))


